MAPT and Alzheimer disease: DLMRI outperforms other neuroimaging biomarkers of neurodegeneration in prodromal AD and the biomarkers of amyloid and tau pathology, which can support the P‐score advanced here as a technical basis because both Feng 2022[52] and this study suggest that the continuous output from the trained DL classification model is reflective of the progressive structural patterns of AD pathology.